NCCN Updates Guidance on Interferon in Essential Thrombocythemia
Key claim: NCCN has granted a category 1 designation for interferon in essential thrombocythemia, signaling a significant upgrade in treatment guidance for this MPN subtype.
Abstract
NCCN granted a category 1 designation for interferon in essential thrombocythemia, with expert commentary noting this represents a significant signal for treatment guidance.
Why this matters
Among MPN subtypes, ET treatment selection has historically been dominated by hydroxyurea and anagrelide, with interferon used selectively. NCCN’s category 1 designation for interferon in ET formally elevates it within this subtype’s treatment algorithm, a contrast to the more established interferon role already recognized in PV and a notable subtype-specific guideline shift worth tracking against future ET prognosis and transformation data.